Genmab — November 2020
-
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4385141-genmab-s-gmab-ceo-jan-van-de-winkel-on-q3-2020-results-earnings-call-transcript?utm_campaign=twitter_automated&utm_content=article&utm_medium=social&utm_source=twitter_automated
-
As you will understand by SITC, you will definitely see a very nice data set from the dose escalation with the PD-L1x4-1BB bispecific antibody. And yes, I think the fact that it has been selected for presentation and highlighting at the press conference probably already tells enough at this point.
-
Aktier/tendens: Genmab, Matas og Vestas i fokus i ventet grøn åbninghttps://www.proinvestor.com/investornyt/669325/aktier-tendens-genmab-matas-og-vestas-i-fokus-i-ventet-gron-abning
-
Genmab-topchef har øget tro til nyt guldhåb
Om kort tid vil Genmab præsentere nye data for cancermidlet epcoritamab, som ifølge topchef Jan van de Winkel vil vise, at midlet er det bedste i sin klasse.
(medwatch.dk)
-
I næste uge lahn1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind